Liberty Health Sciences Announces Record Revenue Increase in Fiscal Year 2020 Financial Results; 401% Growth


Ryan Allway

June 29th, 2020

News, Top News


Combined revenue for the year ended is $50 million

* All references to dollar values refer to Canadian dollars unless otherwise stated.

TORONTOJune 26, 2020 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIFwww.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high quality cannabis, announced its financial results for fiscal year 2020 ending February 29, 2020. Consolidated net sales for fiscal year-end February 29, 2020 were $50,075,579, compared with $10,002,538 for fiscal year-end February 28, 2019.

Liberty’s aggregate operating expenses decreased from $25,588,038 for fiscal year 2019 to $25,184,000 for fiscal year 2020 ending February 29, 2020.

The Company recorded net income for the fiscal year-end February 29, 2020 of $22,266,322, which includes the gain on the sale of a property of $14,266,807, compared with a net loss of $22,293,815 for the fiscal year-end February 28, 2019. The significant year-over-year increase in revenue was driven by the Company’s introduction of more than 200 new products, the opening of new dispensaries, expanded delivery infrastructure, as well as an upsurge in same store sales volume and an increase in registered patient base for Medical Marijuana Use in Florida.

As of February 29, 2020, Liberty maintained $24,957,245 of cash and cash equivalents compared to $13,291,426 in cash and cash equivalents at February 28, 2019.

As of February 29, 2020, Liberty maintained $24,957,245 of cash and cash equivalents compared to $13,291,426 in cash and cash equivalents at February 28, 2019.

Liberty’s product offerings include 11 outstanding quality brands including Liberty Health Sciences, Zentient, Pretty Pistil, Papa’s Herb, Mary’s Medicinals, PAX, GPen, Lemon and Grass, Clarity, DomPen, and Honey Vapes.

The Company has made significant strides in maximizing efficiencies to achieve economies of scale and continues to grow in Florida while steadily expanding its dispensary footprint and product offerings.

“End of year fiscal 2020 proved to be the highest net revenue increase in the Company’s history and reflects our customer loyalty and strength of our brand,” said Victor Mancebo, Chief Executive Officer of Liberty. “Liberty’s continued growth directly ties to the strategic initiatives we have set in place, which has been increasing our Florida production, retail base and delivery footprint along with expanding our product portfolio and brand partnerships. We continue to work on innovative strategies that complement our expansion plans while at the same time provide our patients a more accessible medicine platform.”

Liberty currently operates 25 dispensaries across Florida in the following locations:

•  Boca Raton

•  Palm Harbor

•  Bonita Springs

•  Panama City

•  Bradenton

•  Pensacola

•  Cape Coral

•  Port St. Lucie

•  Dania Beach

•  Sarasota

•  Gainesville

•  St. Petersburg

•  Lakeland

•  Stuart

•  Merritt Island

•  Summerfield

•  Miami

•  Tampa (Hyde Parke)

•  North Miami

•  Tampa (Tetra)

•  Orange Park

•  Tallahassee

•  West Palm Beach

•  Winter Haven

•  Orlando

Operational Highlights:

  • Liberty currently operates 25 dispensaries throughout Florida.

  • Company implemented health and safety measures for employees, patients and facilities following guidance from public health officials worldwide in response to the COVID-19 pandemic to ensure adequate in-store product supply and customer convenience due to increased demand.

  • Liberty has lease agreements in place for 10 additional locations and is negotiating for another ten locations.

  • The Company received Florida Department of Health approval on its LHS360 Innovative Campus, which encompasses a grand total of 190,000 square feet of cultivation space, with an additional 50,000 square feet of processing and manufacturing space.

  • Liberty secured GPM Certification at LHS360 Innovation Campus.

  • In March 2019, Liberty received approval from the Florida Department of Health to dispense flower derived products.

  • In May 2019, Liberty expanded executive leadership team with the appointment of finance veteran, Sheri Cholodofsky to Chief Financial Officer.

  • In June 2019, Liberty introduced Zentient to all of its dispensaries as its new house brand of products along with Pretty Pistil. Zentient represents a line of premium CBD and THC balanced products including topicals, vapes, and oral solutions made from a proprietary formula of ultra-high-quality cannabinoids.

  • The Company entered into an in-licensed agreement with The Werc Shop in June 2019 for its patented and patent-pending terpene technology. The Werc Shop is a world-renowned scientific consulting group recognized as the leaders in cannabis terpene analysis and terpene-based formulations.

  • In August 2019, the Company sold its Chestnut Hill Tree Farm site in Alachua County, Florida, and all its assets in Ohio.

  • Liberty partnered with iHeartJane to offer patients real-time inventory online for an improved shopping experience.

  • In January 2020, Liberty formally appointed Victor Mancebo as President and Chief Executive Officer, as a direct result of Liberty achieving strong results under his leadership as Interim Chief Executive Officer for 12 months.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a high-quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. For more information, please visit: www.libertyhealthsciences.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company’s production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

Related Links

http://www.libertyhealthsciences.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading